ViewRay designs, manufactures and markets the ViewRay MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary magnetic resonance imaging (MRI) system to address the challenges and clinical workflow for radiation oncology. The MRIdian MR-Guided Radiation Therapy System integrates diagnostic-quality MRI with radiation therapy delivery to enable on-table adaptive treatments with real-time tissue tracking and automatic beam gating. Co.'s generations of the MRIdian are: the MRIdian with Cobalt-60 based radiation beams and MRIdian Linac, with linear accelerator or linac based radiation beams. The VRAY average annual return since 2015 is shown above.
The Average Annual Return on the VRAY average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether VRAY average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VRAY average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free VRAY Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
